Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1988 Jun;81(6):1661–1665. doi: 10.1172/JCI113502

Aluminum inhibits erythropoiesis in vitro.

J Mladenovic 1
PMCID: PMC442607  PMID: 3384943

Abstract

Anemia has been associated with aluminum intoxication in patients on chronic dialysis and in animals. In studies presented here, in vitro human erythroid culture was used to delineate the effects of aluminum on normal hematopoiesis. Aluminum by itself in routine culture, even at very high levels (1,035 ng/ml), did not significantly affect erythroid colony growth. The addition of human transferrin to the culture, however, resulted in a marked dose-dependent inhibition of erythroid, but not myeloid colony growth. At all doses, CFU-E progenitors showed greater inhibition than burst-forming units (BFU-E). Aluminum inhibition was not overcome by increasing the dose of erythropoietin or adding additional burst-promoting activity to the culture. Inhibition by aluminum was directly related to the number of binding sites on transferrin in the culture, and was not observed in the presence of fully iron-saturated transferrin.

Full text

PDF
1661

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alfrey A. C., LeGendre G. R., Kaehny W. D. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med. 1976 Jan 22;294(4):184–188. doi: 10.1056/NEJM197601222940402. [DOI] [PubMed] [Google Scholar]
  2. Alfrey A. C., Mishell J. M., Burks J., Contiguglia S. R., Rudolph H., Lewin E., Holmes J. H. Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. Trans Am Soc Artif Intern Organs. 1972;18(0):257-61, 266-7. doi: 10.1097/00002480-197201000-00064. [DOI] [PubMed] [Google Scholar]
  3. Arieff A. I., Cooper J. D., Armstrong D., Lazarowitz V. C. Dementia, renal failure, and brain aluminum. Ann Intern Med. 1979 May;90(5):741–747. doi: 10.7326/0003-4819-90-5-741. [DOI] [PubMed] [Google Scholar]
  4. Berlyne G. M., Adler A. J. Serum aluminum cannot be measured accurately. Am J Kidney Dis. 1985 Nov;6(5):288–292. doi: 10.1016/s0272-6386(85)80080-9. [DOI] [PubMed] [Google Scholar]
  5. Berlyne G. M., Yagil R. Letter: Aluminium-induced porphyria in rats. Lancet. 1973 Dec 29;2(7844):1501–1502. doi: 10.1016/s0140-6736(73)92769-4. [DOI] [PubMed] [Google Scholar]
  6. Bertholf R. L., Wills M. R., Savory J. Quantitative study of aluminum binding to human serum albumin and transferrin by a chelex competitive binding assay. Biochem Biophys Res Commun. 1984 Dec 28;125(3):1020–1024. doi: 10.1016/0006-291x(84)91385-8. [DOI] [PubMed] [Google Scholar]
  7. Boyce B. F., Fell G. S., Elder H. Y., Junor B. J., Elliot H. L., Beastall G., Fogelman I., Boyle I. T. Hypercalcaemic osteomalacia due to aluminium toxicity. Lancet. 1982 Nov 6;2(8306):1009–1013. doi: 10.1016/s0140-6736(82)90049-6. [DOI] [PubMed] [Google Scholar]
  8. Brown S., Bertholf R. L., Wills M. R., Savory J. Electrothermal atomic absorption spectrometric determination of aluminum in serum with a new technique for protein precipitation. Clin Chem. 1984 Jul;30(7):1216–1218. [PubMed] [Google Scholar]
  9. Buchanan M. R., Ihle B. U., Dunn C. M. Haemodialysis related osteomalacia: a staining method to demonstrate aluminium. J Clin Pathol. 1981 Dec;34(12):1352–1354. doi: 10.1136/jcp.34.12.1352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cannata J. B., Ruiz Alegria P., Cuesta M. V., Herrera J., Peral V. Influence of aluminium hydroxide intake on haemoglobin concentrations and blood transfusion requirements in haemodialysis patients. Proc Eur Dial Transplant Assoc. 1983;20:719–724. [PubMed] [Google Scholar]
  11. Coburn J. W., Sherrard D. J., Brickman A. S., Wong E. G., Norman A. W., Singer F. R. A skeletal mineralizing defect in dialysis patients: a syndrome resembling osteomalacia but unrelated to viatamin D. Contrib Nephrol. 1980;18:172–183. doi: 10.1159/000403285. [DOI] [PubMed] [Google Scholar]
  12. Cochran M., Coates J., Neoh S. The competitive equilibrium between aluminium and ferric ions for the binding sites of transferrin. FEBS Lett. 1984 Oct 15;176(1):129–132. doi: 10.1016/0014-5793(84)80926-6. [DOI] [PubMed] [Google Scholar]
  13. Cochran M., Neoh S., Stephens E. Aluminium interaction with 67Ga uptake by human plasma and transferrin. Clin Chim Acta. 1983 Aug 15;132(2):199–203. doi: 10.1016/0009-8981(83)90248-6. [DOI] [PubMed] [Google Scholar]
  14. Day R. S., Eales L., Disler P. B. Porphyrias and the kidney. Nephron. 1981;28(6):261–267. doi: 10.1159/000182215. [DOI] [PubMed] [Google Scholar]
  15. Elliott H. L., Macdougall A. I. Aluminium studies in dialysis encephalopathy. Proc Eur Dial Transplant Assoc. 1978;15:157–163. [PubMed] [Google Scholar]
  16. Eschbach J. W., Egrie J. C., Downing M. R., Browne J. K., Adamson J. W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987 Jan 8;316(2):73–78. doi: 10.1056/NEJM198701083160203. [DOI] [PubMed] [Google Scholar]
  17. Harris D. C., Aisen P. Iron-donating properties of transferrin. Biochemistry. 1975 Jan 28;14(2):262–268. doi: 10.1021/bi00673a011. [DOI] [PubMed] [Google Scholar]
  18. Hodsman A. B., Hood S. A., Brown P., Cordy P. E. Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine? J Lab Clin Med. 1985 Dec;106(6):674–681. [PubMed] [Google Scholar]
  19. Hodsman A. B., Sherrard D. J., Alfrey A. C., Ott S., Brickman A. S., Miller N. L., Maloney N. A., Coburn J. W. Bone aluminum and histomorphometric features of renal osteodystrophy. J Clin Endocrinol Metab. 1982 Mar;54(3):539–546. doi: 10.1210/jcem-54-3-539. [DOI] [PubMed] [Google Scholar]
  20. Hodsman A. B., Sherrard D. J., Wong E. G., Brickman A. S., Lee D. B., Alfrey A. C., Singer F. R., Norman A. W., Coburn J. W. Vitamin-D-resistant osteomalacia in hemodialysis patients lacking secondary hyperparathyroidism. Ann Intern Med. 1981 May;94(5):629–637. doi: 10.7326/0003-4819-94-5-629. [DOI] [PubMed] [Google Scholar]
  21. Huber C. T., Frieden E. The inhibition of ferroxidase by trivalent and other metal ions. J Biol Chem. 1970 Aug 10;245(15):3979–3984. [PubMed] [Google Scholar]
  22. Huebers E., Nelson N. J., Huebers H. A., Rasey J. S. Removal of transferrin from fetal bovine serum. J Lab Clin Med. 1987 Dec;110(6):719–725. [PubMed] [Google Scholar]
  23. Huebers H. A., Finch C. A. Transferrin: physiologic behavior and clinical implications. Blood. 1984 Oct;64(4):763–767. [PubMed] [Google Scholar]
  24. Kaiser L., Schwartz K. A., Burnatowska-Hledin M. A., Mayor G. H. Microcytic anemia secondary to intraperitoneal aluminum in normal and uremic rats. Kidney Int. 1984 Sep;26(3):269–274. doi: 10.1038/ki.1984.169. [DOI] [PubMed] [Google Scholar]
  25. Kaye M. Bone marrow aluminium storage in renal failure. J Clin Pathol. 1983 Nov;36(11):1288–1291. doi: 10.1136/jcp.36.11.1288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. King S. W., Savory J., Wills M. R. The clinical biochemistry of aluminum. Crit Rev Clin Lab Sci. 1981;14(1):1–20. doi: 10.3109/10408368109105861. [DOI] [PubMed] [Google Scholar]
  27. Lestas A. N. The effect of pH upon human transferrin: selective labelling of the two iron-binding sites. Br J Haematol. 1976 Mar;32(3):341–350. doi: 10.1111/j.1365-2141.1976.tb00937.x. [DOI] [PubMed] [Google Scholar]
  28. McCarthy J. T., Milliner D. S., Kurtz S. B., Johnson W. J., Moyer T. P. Interpretation of serum aluminum values in dialysis patients. Am J Clin Pathol. 1986 Nov;86(5):629–636. doi: 10.1093/ajcp/86.5.629. [DOI] [PubMed] [Google Scholar]
  29. McGonigle R. J., Parsons V. Aluminium-induced anaemia in haemodialysis patients. Nephron. 1985;39(1):1–9. doi: 10.1159/000183328. [DOI] [PubMed] [Google Scholar]
  30. Meredith P. A., Moore M. R., Goldberg A. Effects of aluminium, lead and zinc on delta-aminolaevulinic acid dehydratase. Enzyme. 1977;22(1):22–27. doi: 10.1159/000458503. [DOI] [PubMed] [Google Scholar]
  31. Mladenovic J., Adamson J. W. Characteristics of circulating erythroid colony-forming cells in normal and polycythaemic man. Br J Haematol. 1982 Jul;51(3):377–384. doi: 10.1111/j.1365-2141.1982.tb02792.x. [DOI] [PubMed] [Google Scholar]
  32. Molitoris B. A., Alfrey P. S., Miller N. L., Hasbargen J. A., Kaehney W. D., Alfrey A. C., Smith B. J. Efficacy of intramuscular and intraperitoneal deferoxamine for aluminum chelation. Kidney Int. 1987 Apr;31(4):986–991. doi: 10.1038/ki.1987.96. [DOI] [PubMed] [Google Scholar]
  33. O'Hare J. A., Murnaghan D. J. Reversal of aluminum-induced hemodialysis anemia by a low-aluminum dialysate. N Engl J Med. 1982 Mar 18;306(11):654–656. doi: 10.1056/NEJM198203183061107. [DOI] [PubMed] [Google Scholar]
  34. Parkinson I. S., Ward M. K., Kerr D. N. Dialysis encephalopathy, bone disease and anaemia: the aluminum intoxication syndrome during regular haemodialysis. J Clin Pathol. 1981 Nov;34(11):1285–1294. doi: 10.1136/jcp.34.11.1285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Poisson M., Mashaly R., Lebkiri B. Dialysis encephalopathy: recovery after interruption of aluminium intake. Br Med J. 1978 Dec 9;2(6152):1610–1611. doi: 10.1136/bmj.2.6152.1610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Short A. I., Winney R. J., Robson J. S. Reversible microcytic hypochromic anaemia in dialysis patients due to aluminium intoxication. Proc Eur Dial Transplant Assoc. 1980;17:226–233. [PubMed] [Google Scholar]
  37. Sieff C., Bicknell D., Caine G., Robinson J., Lam G., Greaves M. F. Changes in cell surface antigen expression during hemopoietic differentiation. Blood. 1982 Sep;60(3):703–713. [PubMed] [Google Scholar]
  38. Touam M., Martinez F., Lacour B., Bourdon R., Zingraff J., Di Giulio S., Drüeke T. Aluminium-induced, reversible microcytic anemia in chronic renal failure: clinical and experimental studies. Clin Nephrol. 1983 Jun;19(6):295–298. [PubMed] [Google Scholar]
  39. Trapp G. A. Plasma aluminum is bound to transferrin. Life Sci. 1983 Jul 25;33(4):311–316. doi: 10.1016/s0024-3205(83)80002-2. [DOI] [PubMed] [Google Scholar]
  40. Ward M. K., Feest T. G., Ellis H. A., Parkinson I. S., Kerr D. N. Osteomalacic dialysis osteodystrophy: Evidence for a water-borne aetiological agent, probably aluminium. Lancet. 1978 Apr 22;1(8069):841–845. doi: 10.1016/s0140-6736(78)90191-5. [DOI] [PubMed] [Google Scholar]
  41. Wills M. R., Savory J. Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia. Lancet. 1983 Jul 2;2(8340):29–34. doi: 10.1016/s0140-6736(83)90014-4. [DOI] [PubMed] [Google Scholar]
  42. van der Voet G. B., de Wolff F. A. Distribution of aluminium between plasma and erythrocytes. Hum Toxicol. 1985 Nov;4(6):643–648. doi: 10.1177/096032718500400613. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES